Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi gets binding bids for consumer unit
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, Bloomberg News reported on Tuesday. The French pharmaceutical company is likely to make a final decision on the unit in the coming days after reviewing the offers,
Sanofi gets binding bids for consumer unit: Bloomberg News
Sanofi (SNY) has won bindings bids for its consumer health division from private equity firms CD&R and PAI Partners. Read more here.
Sanofi Gets Binding Bids from CD&R, PAI for Consumer Arm
Sanofi has received binding offers for its consumer health division from private equity firms Clayton Dubilier & Rice and PAI Partners, as the French drugmaker inches closer to one of the largest European deals this year,
14h
on MSN
Sanofi consumer care spinoff said to have attracted over €10B from lenders
Banks and other lenders are readying over €10B ($11.1B) in funding as New York-based buyout firm Clayton Dubilier & Rice and ...
FierceBiotech
13h
Months after Frank Nestle’s departure, Sanofi selects new CSO
After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.
STAT
14h
Amid push to redefine itself, Sanofi names new chief scientific officer
Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
1d
Sanofi CEO believes company poised for growth from new drugs
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
ENDPOINTS NEWS
15h
Scoop: Sanofi hires Mike Quigley as next chief scientist, internal memo says
Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma's next chief ...
FierceBiotech
1d
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson's candidate for $27M
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
19h
Sanofi’s Promising Portfolio Drives Buy Rating Amid MS, Cancer Breakthroughs, and Vaccine Expansion
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...
4d
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...
1d
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
FiercePharma
4d
Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
NASDAQ
Ventyx
tolebrutinib
Sarclisa
Paul Hudson
Feedback